喷司他丁(Pentostatin) - 药物靶点：ADA_在研适应症：T细胞白血病，T细胞淋巴瘤，毛细胞白血病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

2'-Deoxycoformycin、Co-vidarabine、DCF

+ [16]

靶点

ADA

作用机制

ADA抑制剂(腺苷脱氨酶抑制剂)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [1]

在研适应症

T细胞白血病T细胞淋巴瘤毛细胞白血病

非在研适应症

急性移植物抗宿主病急性淋巴细胞白血病急性髓性白血病+ [14]

原研机构

Pfizer Inc.

在研机构

KM Biologics KK

Hospira, Inc.Mayne Pharma Group Ltd.

非在研机构

Astex Pharmaceuticals, Inc.

Bayer AG

GSK Plc

+ [2]

最高研发阶段批准上市

首次获批日期

美国 (1991-10-11),

毛细胞白血病

最高研发阶段(中国)-

特殊审评孤儿药 (日本)

登录后查看时间轴

结构/序列

分子式C11H16N4O4

InChIKeyFPVKHBSQESCIEP-JQCXWYLXSA-N

CAS号53910-25-1

关联

54

项与喷司他丁相关的临床试验

NCT05757310

/ Recruiting临床1期IIT

A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Severe Aplastic Anemia Patients With COH-MC-17: A Non-Myeloablative/ Reduced-Intensity, Conditioning Regimen and CD4+ T-Cell-Depleted Haploidentical Hematopoietic Transplant

This phase I trial evaluates the safety and feasibility of using a reduced-intensity regimen of cyclophosphamide, pentostatin, and anti-thymocyte globulin prior to a CD4+ T-cell depleted haploidentical hematopoietic cell transplant (haploHCT) for the treatment of patients with severe aplastic anemia that does not respond to treatment (refractory) or that has come back (recurrent). Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid. It may also lower the body's immune response. Pentostatin blocks a protein needed for cell growth. Anti-thymocyte globulin is an immunosuppressive drug can destroy immune cells known as T-cells. HaploHCT transfers blood-forming stem cells from a healthy partially-matched donor to a patient. Administering a regimen of cyclophosphamide, pentostatin, and anti-thymocyte globulin before haploHCT may help make room for the new, healthy cells and may reduce the risk of graft versus host disease.

开始日期2024-11-15

申办/合作机构

City of Hope National Medical Center

[+1]

ChiCTR2300075075

/ Recruiting临床2期IIT

A Phase IIA Clinical Study of Toripalimab Combined with DCF Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

开始日期2023-09-01

申办/合作机构

福建省立医院.

JPRN-UMIN000047881

/ Recruiting临床2期IIT

Feasibility Study of Preoperative DCF Therapy in Esophageal Cancer - FEVER trial

开始日期2022-10-03

申办/合作机构

Kobe University

100 项与喷司他丁相关的临床结果

登录后查看更多信息

100 项与喷司他丁相关的转化医学

登录后查看更多信息

100 项与喷司他丁相关的专利（医药）

登录后查看更多信息

2,254

项与喷司他丁相关的文献（医药）

2025-04-01·Journal of Environmental Sciences

Construction of bismuth based MOF for efficient removal of sodium diclofenac via adsorption and photocatalysis

Article

作者: Cai, Yanrong ; Chang, Chun ; He, Xiaohui ; Yang, Liping ; Wang, Qiong

The mass production and widespread use of Pharmaceuticals and Personal Care Products (PPCPs) have posed a serious threat to the water environment and public health. In this work, a green metal-based Metal Organic Framework (MOF) Bi-NH₂-BDC was prepared and characterized, and the adsorption characteristics of Bi-NH₂-BDC were investigated with typical PPCPs-diclofenac sodium (DCF). It was found that DCF mainly covered the adsorbent surface as a single molecular layer, the adsorption reaction was a spontaneous, entropy-increasing exothermic process and the adsorption mechanisms between Bi-NH₂-BDC and DCF were hydrogen bonding, π-π interactions and electrostatic interactions. In addition, Bi-NH₂-BDC also had considerable photocatalytic properties, and its application in adsorbent desorption treatment effectively solved the problem of secondary pollution, achieving a green and sustainable adsorption desorption cycle.

2025-03-01·Chemosphere

A high-efficient electrochemical degradation of diclofenac in water on planar and microstructured 2D, and macroporous 3D boron-doped diamond electrodes: Identification of degradation and transformation products

Article

作者: Hojová, Lucia ; Mordačíková, Erika ; Grabic, Roman ; Mackuľak, Tomáš ; Marton, Marián ; Kuchtová, Gabriela ; Michniak, Pavol ; Vojs Staňová, Andrea ; Vojs, Marian ; Grabicová, Kateřina

The highly efficient degradation of persistent organic substances by electrochemical advanced oxidation processes (EAOPs), which don't result in the formation of potentially harmful by-products, is crucial for the future of water management. In this study, boron-doped diamond electrodes (BDDE) with three morphologies (planar 2D, microstructured 2D, and macroporous 3D) were employed for the anodic oxidation of diclofenac (DCF) in two working electrolytes (NaCl and Na₂SO₄). In total, 11 by-products formed during the electrochemical oxidation of DCF were identified via HPLC-HRMS. The identification of degradation products revealed the formation of various active chlorinated species. The utilization of a chlorine-free Na₂SO₄ electrolyte resulted in the formation of greater number of chlorinated species, while their elimination required a longer period compared to the use of NaCl electrolyte. The formation of by-products was also influenced by the specific type of BDD electrode, which was associated with variations in applied current density. This led to an uneven distribution of dichloro (2D BDDE) and trichloro (3D BDDE) patterns. However, none of the products showed signs of a high level of persistence. The results revealed that the type of electrolyte is the most significant factor affecting the removal efficiency of DCF, while the different electrode morphologies do not lead to differences in the removal rates. The electrode type exerted a notable influence on the removal rates, which was associated with varying applied current densities, exclusively in the case of the Na₂SO₄ electrolyte. Over 99 % removal efficiency for DCF in NaCl, with power consumption of 1.8 kWh m^-3 was achieved.

2025-02-01·Journal of Colloid and Interface Science

Degradation of diclofenac sodium by peroxymonosulfate activated with a sulfur-doped chitosan ferrocarbon material: Synergistic interaction of free radical and nonfree radical pathways

Article

作者: Zheng, Junli ; Liu, Yuxin ; Luo, Yang ; Lin, Qintie ; Pan, Jieyi ; Luo, Hao ; Liu, Jiaxin ; Xie, Haijiao ; Zeng, Chen ; Wu, Yajie

The synthesis of efficient and stable peroxymonosulfate (PMS) catalysts by doping naturally degradable and functional group-rich chitosan (CS) with nonmetallic atoms remains challenging. In this study, an environmentally friendly electron-rich S-doped CS ferrocarbon material (Fe-S-CN) was synthesized via the sol-gel method, and the resulting material exhibited excellent catalytic activity (up to 98.6 % diclofenac sodium (DCF) removal in 5 min), wide pH applicability, environmental tolerance and renewability. Moreover, Fe-S-CN synergistically activated PMS via both the radical pathway (superoxide radical (O₂^•-)) and the nonradical pathway (single-linear oxygen (¹O₂) and electron transfer processes (ETP)) to efficiently mineralize DCF. O₂^•- originates from the self-decomposition of PMS, whereas ¹O₂ is due to the oxidation of PMS and further conversion of O₂^•-. In addition, Fe species, graphitic N and thiophene S are the major active sites in Fe-S-CN. The susceptibility sites of DCF and its possible degradation pathways in the Fe-S-CN/PMS system were inferred in conjunction with density functional theory (DFT) calculation. The present study creates a promising scenario for the synergistic effect of easily overlooked heteroatom doping in chitosan iron-carbon materials in the removal of difficult-to-biodegrade organic matter from water bodies.

8

项与喷司他丁相关的新闻（医药）

2024-11-28

·医脉通

“移”路守护，“保”驾护航！芦可替尼慢性移植物抗宿主病适应症纳入医保，为更多慢排患者带来治疗福祉

导言 2024年6月，Janus激酶（JAK）抑制剂芦可替尼获中国国家药品监督管理局（NMPA）批准，用于治疗对糖皮质激素或其他系统治疗应答不充分的12岁及以上慢性移植物抗宿主病（cGVHD）患者，进一步拓宽芦可替尼受益人群。近日，该适应症正式列入国家医保目录，有望提高药物可及性，降低更多中国cGVHD患者负担。专家寄语张曦教授陆军军医大学新桥医院 cGVHD是异基因造血干细胞移植（allo-HSCT）后常见并发症之一，严重影响患者的生存率和生活质量，亟需有效治疗方案以改善患者预后。今年6月，芦可替尼获批治疗激素难治性cGVHD（SR-cGVHD）患者，成为国内首个且目前唯一同时获批急性GVHD（aGVHD）和cGVHD的靶向药物，为GVHD全程管理发展注入新动力。近日，该适应症被纳入国家医保目录，有望提高治疗药物可及性和患者治疗依从性、改善患者生存和生活质量。期待随着芦可替尼的广泛应用，能够为更多患者带来治疗福祉，助力患者重获美好生活！机遇与挑战并存 cGVHD治疗仍存未尽之需造血干细胞移植（HSCT）是治疗多种血液系统恶性肿瘤的有效手段。近年来，中国HSCT领域蓬勃发展，中国造血干细胞移植登记学组报告显示，2022-2023年间，中国移植中心共报告39918例HSCT，其中，allo-HSCT占比69%1，表明allo-HSCT已成为中国HSCT的主要形式。但不容忽视的是，cGVHD仍是患者移植后严重并发症及晚期非复发死亡主要原因，30%-70%患者会发生cGVHD2,3。cGVHD治疗尚存未尽之需：糖皮质激素作为cGVHD一线治疗标准方案疗效有限，约半数患者可进展为SR-cGVHD4，增加非复发死亡率5，而目前尚无标准的优选二线治疗方案；此外，cGVHD治疗周期较长，接受外周血干细胞移植的患者cGVHD中位治疗时间约3.5年6，使得cGVHD患者的器官功能和生活质量大幅下降7。因此，探索快速、高效治疗药物以助力患者实现更优生存。共识与新药赋能中国共识权威引领，芦可替尼提供cGVHD治疗新选择随着新型靶向药物的出现及临床研究的不断推进，cGVHD在诊断、预防、治疗等方面取得了巨大进步，在此背景下，《慢性移植物抗宿主病诊断与治疗中国专家共识（2024年版）》重磅更新，并对cGVHD治疗策略进行优化规范，其中，针对cGVHD二线治疗，共识将芦可替尼作为一种主要的治疗选择，同时指出应根据患者靶器官实际受累情况，选择针对性治疗方法：对于皮肤受累、皮肤硬化型及肝脏受累患者推荐芦可替尼作为第一顺位选择，对于肺受累患者推荐选择阿巴西普、芦可替尼等药物治疗2。作为选择性JAK1/2小分子抑制剂，芦可替尼可通过抑制JAK-STAT信号通路相关细胞和炎症因子，从而作用于cGVHD早期炎症、慢性炎症和器官纤维化的整个阶段8-11，全程抑制cGVHD发展。随机、开放标签、多中心III期REACH3研究显示，与接受最佳可及疗法（BAT，包括体外光分离置换疗法、小剂量甲氨蝶呤、霉酚酸酯、依维莫司/西罗莫司、英夫利昔单抗、利妥昔单抗、喷司他丁、伊马替尼和伊布替尼）治疗的SR-cGVHD患者相比，接受芦可替尼治疗的患者24周总体缓解率（ORR）更高，且任意时间的最佳总体缓解（BOR）更优（图1）12。同时，中国大型系统评价和荟萃分析还显示，接受芦可替尼治疗的SR-cGVHD患者常见受累器官均有良好获益，其中，皮肤、胃肠道和肝脏ORR分别可达84%、71%、70%13，证实芦可替尼在cGVHD患者中的获益。图1.接受芦可替尼及BAT治疗的SR-cGVHD患者治疗结局（A：第24周ORR；B：BOR）医保政策助力医保纳入提高芦可替尼临床可及性，助力更多患者改善预后 2024年，共计162种药品进入国家医保谈判竞价环节，其中，芦可替尼cGVHD适应症纳入本次医保更新目录。该适应症的纳入对于cGVHD领域无疑是利好消息：对于患者而言，医保覆盖可减轻治疗经济负担、满足患者用药需求，促使更多患者能够及时获得治疗，延长生存并改善生活质量；对于领域发展而言，国家医保政策的更新可促进医疗资源合理分配、提高医疗服务的公平性和可及性、推动实现健康中国2030战略目标。期待随着医保政策的逐步落实，更多cGVHD患者可从芦可替尼治疗中受益，提高治疗效果和生活质量，同时，也希望芦可替尼进一步开展研究探索，为更广泛患者带来健康与希望，共同迈向健康中国2030的美好未来。专家简介张曦教授主任医师、教授，博士（后）导师；长江学者特聘教授陆军军医大学新桥医院血液病医学中心主任中国人民解放军血液病中心主任中华医学会血液学分会常务委员、造血干细胞应用学组副组长中国抗癌协会血液肿瘤专委会副主任委员中国医师协会血液科医师分会常务委员中国血液病专科联盟副理事长中国病理生理学会实验血液学专委会常务委员 Blood & Genomics杂志主编主持国家、省部级课题46项；SCI论文143篇，主编专著3部，副主编3部；第一完成人获国家科技进步二等奖1项、中华医学科技一等奖1项、重庆市科技进步一等奖3项、二等奖1项，执笔行业指南12项，参编50项；获国家发明专利68项获中国肿瘤青年科学家奖、陆军优秀科技人员标兵、重庆市首席专家工作室和重庆市创新群体领衔专家、重庆市首席医学专家、重庆市科技创新领军人才、天府学者特聘专家、全军拔尖人才、首批陆军科技英才；The Lancet，JCO，Blood，JHO，Leukemia，The Lancet Haematology，Science Bulletin，CMJ，Nat Cell Biol 等杂志编委和审稿专家王筱淇博士医学博士，陆军军医大学新桥医院血液病医学中心副主任医师重庆市医师协会血液科医师分会委员，Blood&Genomics Associate Editor 从事造血干细胞移植并发症的相关机制研究，在J Clin Invest.（2020、2023）、J Hematol Oncol. 、Haematologica、Leukemia、 Acta Biomater. 等杂志发表学术论文10余篇，影响因子＞10分 6篇，参编专著1部，主持国家自然科学基金、省部级及校级课题3项，作为课题骨干参与国家级省部级重点项目4项，执笔共识1部，参编行业指南3项，陆军军医大学“红医苗圃”，国防科技三等功，“四有”优秀文职人员，重庆市科技进步一等奖完成人之一。参考文献： 1.Xu LP,et al.Bone Marrow Transplant.2024 Sep 25. 2.中华医学会血液学分会干细胞应用学组.中华血液学杂志.2024;45(8):713-726. 3.Miklos D,et al.Blood.2017;130(21):2243-2250. 4.Wu H, et al.JAMA Netw Open. 2021 Jan 4;4(1):e2034750. 5.Axt L, et al.Bone Marrow Transplant.2019;54:1805-14. 6.徐开林.中华血液学杂志.2018;(2):89-93. 7.王筱淇,等.临床血液学杂志.2024;37(9):597-601. 8.Schroeder MA,et al.Dis Model Mech.2011;4(3):318-333. 9.Zeiser R,et al.N Engl J Med.2017;377(26):2565-2579. 10.Schroeder MA,et al.Biol Blood Marrow。Transplant.2018;24(6):1125-1134. 11.张会,等.临床内科杂志.2021;38 (7):499-501. 12.Zeiser R, et al. N Engl J Med. 2021;385:228-238. 13.Xu Yang,et al.Blood (2022)140(Supplement 1):12888–12889. 审批码JAK0034683-79788，有效期为2024-11-26至2025-11-25，资料过期，视同作废

2024-02-29

·Pharmaceutical Technology

NHS expedites availability of Belumosudil for chronic GVHD

The once-daily tablet hinders proteins that trigger the severe inflammatory response linked to chronic GVHD. Credit: fizkes / Shutterstock.com. The National Health Service (NHS) in the UK has expedited the availability of the new drug, Belumosudil (Rezurock), for cancer patients with chronic graft versus host disease (GVHD). The decision provides a treatment that can be administered in the at-home setting, reducing hospital visits. Administered as a once-daily tablet, Belumosudil hinders proteins that trigger the severe inflammatory response linked to chronic GVHD. Clinical trials have demonstrated that up to three-quarters of the subjects responded to the therapy, with significant effectiveness in treating symptoms affecting the mouth, intestine or joints. The treatment is accessible through the NHS England’s Innovative Medicines Fund, which fast-tracks the delivery of the most promising non-cancer drugs to patients. See Also: AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront DNTH-103 by Dianthus Therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval Chronic GVHD is a rare but serious condition that can occur after a life-saving stem cell transplant. White blood cells in the donated tissue attack the patient’s organs and weaken their immune system. Approximately one-third of patients who receive stem cell or bone marrow transplants for blood cancers such as leukaemia and lymphoma can develop chronic GVHD. Around 1,200 patients in England undergo such transplants each year. Around 400 go on to develop the condition, which is sometimes mild but for one in ten cases is fatal. For half of patients with chronic GVHD, existing therapies such as pentostatin, rituximab and imatinib are ineffective. Belumosudil will now be made available for 200 severely affected patients who have not responded to two previous therapies. This development comes after the NHS decided to fast-track the funding for the drug based on clinical guidance from the UK National Institute of Health and Care Excellence ( Nice ). Belumosudil is the fourth therapy offered to patients through the Innovative Medicines Fund. In September 2023, the NHS used the fund to roll out Sebelipase alfa, a therapy for treating Wolman’s disease, a rare genetic ailment. NHS England specialised services medical director James Palmer stated: “This rollout is a real breakthrough for patients with graft versus host disease and it will help people living with this debilitating condition effectively manage their symptoms and enhance their quality of life and daily functioning. “It’s great news that the NHS has been able to fast-track funding for a treatment which will have a significant impact for hundreds of patients over the coming years.”

临床结果

2023-04-03

·Firstwordpharma

CMS trims first list of drugs tapped for inflation fines

The US Centers for Medicare and Medicaid Services (CMS) has quietly updated the list of Part B prescription medicines subject to penalties because their prices rose faster than the rate of inflation. In an update late last week, the agency cut seven medicines from its original list of 27 that was unveiled on March 15.A provision in the Inflation Reduction Act (IRA), which came into force last year, penalises pharmaceutical companies for charging prices that go up faster than inflation for people with disabilities or those 65 and older who are on the government's Medicare health programme (for more, see ViewPoints: Inflation Reduction Act's myriad impacts to reverberate across pharma). The move is expected to lower out-of-pocket costs for some Medicare recipients by between $1 and $372 per average dose, as of April 1, depending on their individual coverage, according to an agency press release updated on March 30.Gilead cell therapies knocked off The seven drugs that have been cut from the original list include Gilead Sciences' CAR-T therapies Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel); Stemline Therapeutics' Elzonris (tagraxofusp-erzs) used for blastic plasmacytoid dendritic cell neoplasm; Shionogi's Fetroja (cefiderocol), an antibiotic to treat complicated urinary tract infections; Arcotech Biopharma's Folotyn (pralatrexate) for relapsed or refractory peripheral T-cell lymphoma; Kamada's WinRho SDF (Rhₒ(D) immune globulin) to boost platelet counts in order to prevent excessive haemorrhage; and Bausch + Lomb's Xipere (triamcinolone acetonide), which is prescribed for macular oedema associated with uveitis.CMS did not give a reason for why the original list was scaled back. Other products that remain include all five Pfizer drugs that were on the original list, namely Atgam (antithymocyte globulin equine), Bicillin L-A (penicillin G benzathine), Bicillin C-R (penicillin G benzathine and penicillin G procaine), Fragmin (dalteparin) and Nipent (pentostatin), as well as Johnson & Johnson's Rybrevant (amivantamab). Companies whose products have been flagged will be required to pay Medicare the difference in the form of a rebate ranging from roughly 14% to 20%. Meanwhile, CMS has said that by September 1, it plans to publish the first 10 Medicare Part D drugs that will be subject to government price negotiations starting in 2026.

生物类似药上市批准加速审批申请上市专利到期

100 项与喷司他丁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00155	喷司他丁	L01XX08	DB00552

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
T细胞白血病	日本	KM Biologics KK	1994-04-01
T细胞淋巴瘤	日本	KM Biologics KK	1994-04-01
毛细胞白血病	美国	Hospira, Inc.	1991-10-11

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
多发性骨髓瘤	申请上市	美国	Astex Pharmaceuticals, Inc.	2000-12-08
骨髓增生异常综合征	申请上市	美国	Astex Pharmaceuticals, Inc.	2000-12-08
外周T细胞淋巴瘤	申请上市	美国	Astex Pharmaceuticals, Inc.	2000-12-08
费城染色体阳性慢性粒细胞白血病	申请上市	美国	Astex Pharmaceuticals, Inc.	2000-12-08
慢性淋巴细胞白血病	临床前	美国	Astex Pharmaceuticals, Inc.	2003-12-01
慢性淋巴细胞白血病	临床前	美国	Astex Pharmaceuticals, Inc.	2003-12-01
移植物抗宿主病	临床前	美国	Astex Pharmaceuticals, Inc.	2002-04-01
急性髓性白血病	临床前	美国	Astex Pharmaceuticals, Inc.	2000-12-08
霍奇金淋巴瘤	临床前	美国	Astex Pharmaceuticals, Inc.	2000-12-08
类风湿关节炎	临床前	美国	Astex Pharmaceuticals, Inc.	1996-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02105766 (CTgov)	临床2期	β地中海贫血 \| 造血干细胞移植 \| 镰状细胞血症 \| 移植物抗宿主病	56	Radiotherapy+cyclophosphamide+Sirolimus+Pentostatin+Alemtuzumab (Female Participants With SCD or Beta-thalassemia Receiving Stem Cell Transplant With Male Donor)	衊憲壓築糧鏇窪構製鹽(簾顧憲獵餘簾觸顧壓選) = 鑰壓簾鹽構窪觸淵衊願鏇鑰蓋觸壓艱遞遞範齋 (糧選淵窪願製範鹽鏇選, 鏇觸餘選衊壓獵淵範醖 ~ 餘廠淵選艱製鬱遞餘醖) 更多	-	2024-11-29
NCT02105766 (CTgov)	临床2期	β地中海贫血 \| 造血干细胞移植 \| 镰状细胞血症 \| 移植物抗宿主病	56	Radiotherapy+cyclophosphamide+Sirolimus+Pentostatin+Alemtuzumab (Participants With Pre-existing Antibodies and SCD or Beta-thalassemia Receiving Stem Cell Transplant)	醖鏇廠淵範觸壓鑰願醖(窪醖選廠襯廠顧遞膚餘) = 遞鬱襯廠範積鹽遞顧廠窪鑰獵醖齋糧壓齋淵醖 (夢範淵襯願膚廠積範夢, 鹽夢鹹鬱獵簾窪鑰艱廠 ~ 遞鏇憲願憲衊構網襯構) 更多	-	2024-11-29
NCT03077542 (CTgov)	临床1/2期	镰状细胞血症	57	Filgrastim	積簾鹽鹹醖蓋鬱淵鏇範(觸鹽構鏇艱蓋簾餘醖衊) = 窪淵餘蓋積製鹽憲遞淵淵網簾簾鹽選糧淵襯膚 (鑰繭壓遞衊窪鬱願網範, 鑰簾選鬱糧襯襯遞憲願 ~ 廠鹹夢遞窪選醖積簾衊) 更多	-	2024-08-07
NCT01059786 (CTgov)	临床2期	毛细胞白血病	69	Corticosteroids+Bronchodilators+Bendamustine+Acetaminophen+Epinephrine+Intravenous (IV) Saline+Pentostatin+Diphenhydramine+Rituximab	(窪鬱鬱壓鑰願積願鹹糧) = 襯網壓憲遞簾蓋蓋窪築醖壓壓膚顧窪憲壓醖鹽 (觸獵築構觸繭構鏇齋壓, 廠襯構襯鹽淵醖衊積蓋 ~ 構鑰獵餘製積積網簾選) 更多	-	2024-05-01
Tandem Meetings ASTCT and CIBMTR2023	N/A	T细胞淋巴瘤	10	Pentostatin	積簾鏇餘積選膚蓋窪鏇(獵壓鑰簾網製顧願艱蓋) = Four (40%) patients had CMV reactivation during follow-up 積鹹膚襯窪製鹹蓋憲鏇 (簾鬱鬱鏇網艱願淵襯膚 ) 更多	积极	2023-02-01
Tandem Meetings ASTCT and CIBMTR2023	N/A	T细胞幼淋巴细胞白血病	9	Pentostatin 8mg/m2 CIVI over 48h and 600cGy TBI in 3 200cGy fractions	淵膚鹹遞鏇鹽繭膚餘獵(淵願餘糧淵餘築遞築製) = One patient (11%) had CMV reactivation 齋艱夢淵襯淵簾膚繭廠 (構構觸衊鹹憲簾獵鹽觸 ) 更多	积极	2023-02-01
Tandem Meetings ASTCT and CIBMTR2023	N/A	造血干细胞移植	26	Pentostatin	鹹鹹觸憲壓膚窪網廠鏇(夢糧鬱積廠範獵簾範窪) = Two grade II cutaneous acute graft-versus-host-disease (aGVHD) 衊蓋餘糧鬱壓顧廠衊憲 (繭選積憲鏇繭範鬱願醖 ) 更多	积极	2023-02-01
ASCO_GI2023	N/A	食管腺癌新辅助	225	DCF - Docetaxel/Cisplatin/5FU	(顧積鏇淵鹽選鑰艱蓋築) = 壓選製鹹網鬱製淵餘鬱觸憲願鏇鹽廠獵簾鬱獵 (壓淵壓醖簾鏇築糧糧範 ) 更多	-	2023-01-24
ASCO_GI2023	N/A	食管腺癌新辅助	225	FLOT - 5FU, Leucovorin, Oxaliplatin, and Docetaxel	(顧積鏇淵鹽選鑰艱蓋築) = 製鹹網願膚構艱夢醖膚觸憲願鏇鹽廠獵簾鬱獵 (壓淵壓醖簾鏇築糧糧範 ) 更多	-	2023-01-24
ASCO_GI2021	N/A	胃食管交界处腺癌	32	Preoperative DCF chemotherapy	鹹鏇醖製襯鑰襯鏇艱鏇(淵鑰憲願餘襯繭獵遞襯) = 繭壓鹹襯憲壓鬱艱醖顧蓋範糧鏇積遞蓋遞衊蓋 (獵選鬱範窪蓋構遞衊獵 ) 更多	-	2021-01-22
ASCO_GI2020	N/A	食管癌新辅助	58	DCF (CMR group)	(築衊鬱齋淵壓壓鹹鏇淵) = 窪網衊網網艱鏇選顧觸觸艱築範鹹淵衊鏇衊選 (齋鹹繭鏇構壓齋獵顧積 ) 更多	不佳	2020-02-04
ASCO_GI2020	N/A	食管癌新辅助	58	DCF (non-CMR group)	(築衊鬱齋淵壓壓鹹鏇淵) = 夢壓選網壓繭選壓顧鬱觸艱築範鹹淵衊鏇衊選 (齋鹹繭鏇構壓齋獵顧積 ) 更多	不佳	2020-02-04
NCT00074282 (E2903, CTgov)	临床2期	慢性淋巴细胞白血病	102	Cyclophosphamide+pentostatin+Rituximab (Arm A (PCR))	(窪壓製壓繭鑰觸選繭築) = 觸廠齋觸艱蓋蓋衊獵觸糧憲齋繭蓋鬱鹽憲築艱 (鏇獵簾醖鬱簾鬱醖築膚, 選艱簾選製範選網膚範 ~ 網鏇廠膚衊夢蓋窪繭窪) 更多	-	2019-02-27
NCT00074282 (E2903, CTgov)	临床2期	慢性淋巴细胞白血病	102	Alemtuzumab (Arm B (Alemtuzumab: CR, nPR))	鑰廠遞糧鹽蓋遞鹽壓願(鹹簾築鏇鹹鏇製艱鬱餘) = 築餘膚壓艱願網願網鹽憲餘構蓋選網願醖築顧 (構糧製鬱鬱衊膚艱製鹽, 願廠築淵廠製壓蓋餘積 ~ 築襯鑰鏇簾鏇齋選選觸) 更多	-	2019-02-27